Provided by Tiger Fintech (Singapore) Pte. Ltd.

ProMIS Neurosciences Inc

0.4401
-0.0300-6.38%
Post-market: 0.44980.0097+2.20%18:00 EDT
Volume:396.26K
Turnover:183.34K
Market Cap:14.39M
PE:-14.02
High:0.4900
Open:0.4900
Low:0.4384
Close:0.4701
Loading ...

ProMIS Neurosciences Rises; HC Wainwright Starts Coverage With $4 Target

Dow Jones
·
15 Jul

ProMIS Neurosciences Considers Reverse Stock Split to Meet Nasdaq Compliance

Reuters
·
08 Jul

Michael S. Gordon, 10% Owner, Reports Disposal of Common Shares in ProMIS Neurosciences Inc

Reuters
·
03 Jul

ProMIS Neurosciences Inc. Conducted Annual Stockholders Meeting

Reuters
·
13 Jun

ProMIS Neurosciences Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
13 May

ProMIS Neurosciences Initiated at Buy by Maxim Group

Dow Jones
·
12 May

ProMIS Neurosciences Q1 EPS $(0.21) Misses $(0.12) Estimate

Benzinga
·
12 May

ProMIS Neurosciences Inc expected to post a loss of 12 cents a share - Earnings Preview

Reuters
·
09 May

Press Release: Vera Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

Dow Jones
·
06 May

ProMIS Neurosciences Price Target Maintained With a $6.00/Share by Guggenheim

Dow Jones
·
01 Apr

ProMIS Neurosciences Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
01 Apr

ProMIS Neurosciences FY 2024 GAAP EPS $0.11 May Not Be Comparable To $(0.06) Estimate

Benzinga
·
31 Mar

ProMIS Neurosciences reports FY24 EPS 11c vs. ($1.07) last year

TIPRANKS
·
31 Mar

ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights

GlobeNewswire
·
31 Mar

ProMIS Neurosciences Inc expected to post a loss of 14 cents a share - Earnings Preview

Reuters
·
29 Mar

Danantara Won't Pledge Government Shares, Says Deputy Minister of Finance

Tempo
·
14 Mar

Press Release: Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Dow Jones
·
26 Feb

ProMIS Neurosciences Inc - Six-Month Interim Results Expected in 1H 2026, Topline Results in 2H 2026

THOMSON REUTERS
·
25 Feb

ProMIS Neurosciences Doses First Patients in Phase 1B Precise-Ad Trial of Pmn310 for Alzheimer’s Disease

THOMSON REUTERS
·
25 Feb

ProMIS Neurosciences Inc - Precise-Ad Study to Enroll Approximately 100 Subjects Across 22 Sites

THOMSON REUTERS
·
25 Feb